Business Context and Reporting Period
vTv Therapeutics Inc. (NASDAQ: VTVT) is a clinical-stage pharmaceutical company focused on treating metabolic and inflammatory diseases. Its lead program is cadisegliatin, a liver-selective glucokinase activator for Type 1 diabetes. This Form 10-Q covers the quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | Balance Sheet (June 30, 2024) |
|---|---|---|---|
| Revenue | $0 | $1,000 | N/A |
| Net Loss (Attributable to vTv) | $(5,180) | $(10,045) | N/A |
| Operating Loss | $(7,155) | $(12,782) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $45,526 |
| Accumulated Deficit | N/A | N/A | $(291,301) |
| Net Cash Used in Operating Activities | N/A | $(14,064) | N/A |
| Net Cash Provided by Financing Activities | N/A | $50,144 | N/A |
Note: Revenue for the six months ended June 30, 2024, consists of a $1.0 million milestone payment from the Newsoara License Agreement. There was no revenue in the three months ended June 30, 2024.
Material Changes vs. Prior Period
- Revenue: The company recognized $1.0 million in revenue for the six months ended June 30, 2024, compared to $0 in the same period in 2023. This was due to a development milestone satisfaction under the Newsoara License Agreement.
- Operating Expenses: Total operating expenses decreased by $1.6 million (10.7%) for the six months ended June 30, 2024, compared to the prior year period.
- R&D Expenses: Decreased by $2.5 million (29.5%) to $6.1 million, primarily driven by lower spending on cadisegliatin toxicity studies and manufacturing costs.
- G&A Expenses: Increased by $0.9 million (13.2%) to $7.7 million, driven by higher payroll and legal expenses.
- Liquidity: Cash and cash equivalents increased significantly from $9.4 million at December 31, 2023, to $45.5 million at June 30, 2024. This increase was primarily due to a private placement financing in February 2024 that raised approximately $51.0 million in gross proceeds.
- Other Income/Expense: Other income (expense) net turned negative for the six months ended June 30, 2024 ($(0.2) million), compared to a positive $2.2 million in the prior year, largely due to the absence of unrealized gains on equity investments in Reneo Pharmaceuticals and changes in warrant fair values.
Guidance, Outlook, Risks, and Unusual Items
- Clinical Hold (Critical Risk): On July 26, 2024 (subsequent to the reporting period), the FDA placed a clinical hold on the cadisegliatin clinical program, including the ongoing CATT1 Phase 3 trial. This was due to an unresolved chromatographic signal in a recent ADME study. The company must complete a single in vitro study to characterize the signal before trials can resume. No patients had been dosed in the CATT1 trial at the time of the hold.
- Liquidity Outlook: Management believes current cash resources ($45.5 million) are sufficient to meet liquidity requirements for at least the next twelve months, including funding activities to address the clinical hold.
- Financing: The company entered into a $50.0 million "At-The-Market" (ATM) sales agreement with TD Cowen in February 2024. No shares have been sold under this agreement as of June 30, 2024.
- Collaboration Agreements:
- Newsoara: Entered a second amendment in June 2024 expanding the global license contingent on a $20.0 million upfront fee (payable within one year).
- G42: Continuing collaboration for cadisegliatin development in the Middle East, Africa, and Central Asia.
- Unusual Items: The company reclassified $5.3 million of redeemable noncontrolling interest to permanent equity in February 2024 following changes to governance rights with MacAndrews & Forbes.
Key Facts for Investor Verification
- FDA Clinical Hold Status: Verify the timeline and requirements for lifting the clinical hold on the cadisegliatin program and the potential impact on the CATT1 trial and future development costs.
- Newsoara Upfront Payment: Confirm whether the $20.0 million upfront fee from the Newsoara License Agreement amendment is received within the one-year window, as failure to pay will nullify the amendment.
- Cash Burn Rate: Monitor the rate of cash consumption given the pause in clinical trials and the need for additional funding to resolve the FDA hold and resume operations.
- ATM Offering Utilization: Track any sales under the $50.0 million ATM facility with TD Cowen, which could impact share count and dilution.
- Warrant Liability Volatility: Note the significant fluctuations in warrant liabilities (related party and non-related party) which impact net loss but are non-cash items.